Stallion India Fluorochemicals is a fluorochemical and industrial gas company that currently earns most of its revenue from trading and distribution of refrigerants and specialty gases across India and 15+ countries, with a pan-India network and over 200 customers. The core distribution business generates a PAT margin of around 10%, as seen in FY26 when revenue was ₹431 crore and PAT ₹43.84 crore. The company is now investing heavily to become a manufacturer, with a 10,000 MT R-32 plant at Bhilwara, a 1,200 MT helium plant at Khalapur, and an HFO blending and semiconductor gas facility at Mumbattu. These new manufacturing assets are expected to lift PAT margins to 16-24% for new products, but the current business remains a lower-margin trading operation. The competitive structure is fragmented with a few large players like Navin and SRF, but Stallion's aftermarket focus and distribution reach give it a niche position.
The economics persist because of several underappreciated barriers. Semiconductor and high-purity gas qualification cycles take 2-3 years, and once qualified, customers do not easily switch, creating sticky revenue. The company has a 20-year association with Honeywell, which safeguards IP and provides credibility. Helium sourcing is secured through a strategic tie-up with Sharjah Oxygen, with swap arrangements to de-risk supply from the Middle East. The R-32 plant benefits from government quota allocation, and Stallion expects to receive the full 10,000 MT quota, which limits new entrants. Additionally, the Mumbattu facility is scaled to 12 tanks, designed to meet needs for the next decade, and the company's backward integration into R-32 will feed captive HFO blending, reducing import reliance. While R-32 itself is becoming a commodity with multiple domestic capacities coming up (70,000-90,000 tons vs India demand of ~20,000 tons), Stallion's captive consumption and export potential provide a buffer.
The inflection is the commissioning of the R-32 plant, now expected by December 2026 (delayed from October), with revenue contribution of ~₹125 crore in Q4 FY27. The helium plant is operational from Q2 FY27, and Mumbattu is operational from August 2026. By 18-24 months from now, which is roughly FY28 and early FY29, the R-32 plant should be running at full capacity, generating full-year revenue of ₹500-600 crore in FY28. Helium volumes are expected to ramp from 5 containers in the first year to 12 in the next, and then 24. Mumbattu will add HFO blending and semiconductor gas handling, enabling local production and reducing import reliance. Management guides that when all three plants are operational, peak revenue will exceed ₹1,100 crore with a minimum 15% PAT margin. The HFO manufacturing plant, with capex of ₹350-400 crore, is planned to be announced towards the end of FY27 and built after R-32 stabilizes, which would extend growth beyond the 24-month horizon.
Management has a mixed track record. In FY26, they initially guided 30% YoY growth (implying ~₹490 crore) but revised down to ₹430 crore mid-year and then delivered exactly ₹430 crore, with PAT of ₹43.84 crore, meeting the revised guidance. However, plant timelines have slipped repeatedly: Khalapur and Mumbattu were originally slated for Dec-25/Jan-26, then moved to March/April-26, and finally to June and August 2026 respectively. The R-32 plant was promised for October 2026 but is now December 2026. Management attributes delays to scaling up facilities (Mumbattu from 5 to 12 tanks) and monsoon issues. They have maintained the 30-35% revenue CAGR guidance for three years and expect margin improvement of 3-4%. They raised ₹364 crore via a rights issue to fund the Bhilwara plant and state no further dilution is expected, with future capex funded from internal accruals and PAT. Cash balance stood at ~₹434 crore, and they have an unutilized OD facility of ₹120 crore.
The quantified earnings path: FY27 PAT is likely to be around ₹75-80 crore, based on core business PAT of ~₹43 crore, R-32 contribution of ~₹30 crore (₹125 crore revenue at 24% PAT margin), and small helium revenue. For FY28, with full-year R-32 revenue of ₹500-600 crore at 24% PAT margin, plus core business and helium/Mumbattu, PAT could reach ₹150-200 crore, aligning with the peak revenue of ₹1,100 crore and 15% PAT margin. The key assumptions are that the R-32 plant starts by December 2026, receives the full 10,000 MT quota, and that helium supply remains stable. The single most important watchpoint is the government's R-32 quota allocation, which has not yet been declared; if Stallion receives less than 10,000 MT, revenue will be lower. Additionally, the oversupply of R-32 in India (70-90k tons capacity vs 20k demand) could pressure prices, but management expects export and blends to absorb. The falsifier is any further delay in R-32 commissioning or a quota shortfall, which would push the j-curve further out.
companyname: Stallion India Fluorochemicals Limited ticker: STALLION sector: Fluorochemicals / Refrigerant & Specialty Industrial Gases Stallion India Fluorochemicals is a Mumbai-based processor, blender, and distributor of refrigerant and specialty industrial gases. It imports refrigerants in bulk, debulks them into cylinders, blends them into formulations, and distributes them across India through four operational facilities. The company does not manufacture refrigerant molecules today, but t...
Read the full report →capex, margin expansion, new product segment, geographic expansion
FY27 revenue growth guided at 30-35% CAGR over next three years driven by backward integration, specialty product expansion; margin improvements of 3-4%
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Stallion India Fluorochemicals Ltd. and 4,900+ companies.
5-day free pass. No card required.